$BSX

$BSX shares dropped 9.02% to 52-week lows despite positive WATCHMAN FLX and EKOS trial results, signaling investor caution amid broader growth concerns.

U.S. stocks rally as Fed Chair Powell signals no imminent rate hikes and Trump discloses Iran negotiations, boosting equities across sectors.

Portnoy Law Firm files class action lawsuit against Boston Scientific for allegedly misleading investors about growth prospects and competitive pressures in electrophysiology market.

Rosen Law Firm urges $BSX investors to join securities lawsuit alleging false statements about U.S. Electrophysiology segment sustainability. Lead plaintiff deadline: May 4, 2026.

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

Boston Scientific faces class action over false electrophysiology segment statements. Investors from July 2025–February 2026 may recover damages; lead plaintiff deadline May 4, 2026.

Securities lawsuit alleges $BSX made false statements about electrophysiology sustainability. Investors who bought stock July 2025-February 2026 may qualify for compensation.

Boston Scientific faces class action lawsuit after 17% stock decline following $0.45 EPS miss versus $0.48-$0.52 guidance, amid alleged undisclosed Electrophysiology market share losses.

Class action lawsuit alleges Boston Scientific made false statements about U.S. electrophysiology segment sustainability, citing undisclosed competitive pressures and regulatory headwinds affecting procedure volumes.

Robbins Geller launches class action lawsuit against $SNOW, alleging securities fraud over false product efficiency claims and material business disclosures between June 2023 and February 2024.

Three companies face class action lawsuits alleging securities fraud. Boston Scientific stock fell 17% after missing earnings guidance amid alleged false revenue projections.

Class action filed against $BSX alleging executives misrepresented U.S. electrophysiology segment sustainability. Claims executives concealed adverse trends, competitive pressures, regulatory challenges.

Law firm investigates $BSC for allegedly misleading investors about U.S. Electrophysiology growth sustainability and competitive pressures during July 2025-February 2026 period.

Rosen Law Firm sued $ENPH for allegedly misleading investors on inventory management and financial prospects amid tax credit concerns.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability and concealed adverse facts.

Boston Scientific faces class action lawsuit alleging misleading statements about electrophysiology market position, with stock down 17% after missing earnings guidance.

Class action lawsuit filed against $BSX alleging executives made false statements about U.S. electrophysiology segment sustainability, concealing competitive pressures and regulatory headwinds.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability, resulting in earnings miss and weak guidance.

Class action lawsuit filed against $BSX over alleged misrepresentations in U.S. electrophysiology segment between July 2025 and February 2026.

Law firm Levi & Korsinsky files class action against Boston Scientific, citing misleading statements. Stock tumbled 17.6% after disappointing Q4 2025 earnings and weak 2026 guidance.